JPWO2021214117A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021214117A5
JPWO2021214117A5 JP2022563872A JP2022563872A JPWO2021214117A5 JP WO2021214117 A5 JPWO2021214117 A5 JP WO2021214117A5 JP 2022563872 A JP2022563872 A JP 2022563872A JP 2022563872 A JP2022563872 A JP 2022563872A JP WO2021214117 A5 JPWO2021214117 A5 JP WO2021214117A5
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
aryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522124A5 (https=
JP2023522124A (ja
Publication date
Priority claimed from EP20170641.3A external-priority patent/EP3901151B1/en
Application filed filed Critical
Publication of JP2023522124A publication Critical patent/JP2023522124A/ja
Publication of JP2023522124A5 publication Critical patent/JP2023522124A5/ja
Publication of JPWO2021214117A5 publication Critical patent/JPWO2021214117A5/ja
Pending legal-status Critical Current

Links

JP2022563872A 2020-04-21 2021-04-21 ハロゲン化ヘテロアリール及び他のヘテロ環系キナーゼ阻害剤、及びその用途 Pending JP2023522124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170641.3A EP3901151B1 (en) 2020-04-21 2020-04-21 Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
EP20170641.3 2020-04-21
PCT/EP2021/060338 WO2021214117A1 (en) 2020-04-21 2021-04-21 Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof

Publications (3)

Publication Number Publication Date
JP2023522124A JP2023522124A (ja) 2023-05-26
JP2023522124A5 JP2023522124A5 (https=) 2024-04-18
JPWO2021214117A5 true JPWO2021214117A5 (https=) 2024-04-18

Family

ID=71108343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563872A Pending JP2023522124A (ja) 2020-04-21 2021-04-21 ハロゲン化ヘテロアリール及び他のヘテロ環系キナーゼ阻害剤、及びその用途

Country Status (18)

Country Link
US (1) US20230348453A1 (https=)
EP (2) EP3901151B1 (https=)
JP (1) JP2023522124A (https=)
KR (1) KR20230015343A (https=)
CN (1) CN115667255B (https=)
AU (1) AU2021258431A1 (https=)
BR (1) BR112022021476A2 (https=)
CA (1) CA3176325A1 (https=)
CL (1) CL2022002899A1 (https=)
CO (1) CO2022016245A2 (https=)
CR (1) CR20220528A (https=)
IL (1) IL297481A (https=)
MX (1) MX2022013160A (https=)
PE (1) PE20230462A1 (https=)
PH (1) PH12022552813A1 (https=)
TW (1) TW202204352A (https=)
WO (1) WO2021214117A1 (https=)
ZA (1) ZA202212631B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
KR20240115232A (ko) * 2021-10-19 2024-07-25 아이오엠엑스 테라퓨틱스 아게 Sik3 억제제 및 이의 중간체를 제조하기 위한 합성 반응식 및 과정
US20230212522A1 (en) * 2022-01-05 2023-07-06 The Board Of Regents Of The University Of Texas System Methods and reagents for characterizing thsd1 function
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861A1 (en) 2024-04-30 2025-11-05 iOmx Therapeutics AG A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE394102T1 (de) * 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
RU2368602C2 (ru) 2005-01-26 2009-09-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US20100113520A1 (en) * 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN103172627B (zh) * 2011-12-26 2015-11-18 南京优科生物医药有限公司 杂环嘧啶苯或吡啶苯类化合物及其应用
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
CN106699744B (zh) * 2015-11-18 2021-05-11 四川海思科制药有限公司 一种杂环类酰胺衍生物及其制备方法和在药学上的应用
BR112019017741A2 (pt) 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
DK3391907T3 (da) 2017-04-20 2020-03-09 Iomx Therapeutics Ag Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf
DK3643713T3 (da) * 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse

Similar Documents

Publication Publication Date Title
IL297481A (en) Halogenated heteroaryls and other heterocyclic kinase inhibitors, and uses thereof
US12268666B2 (en) Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
JP7728367B2 (ja) がんを処置するために使用され得る尿素誘導体
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
JP2020002146A (ja) イブルチニブ併用療法
IL298300A (en) 4-oxo-3,4-dihydroquinazolinone compounds for the treatment of braf-related diseases and disorders
WO2022221227A9 (en) Amino-substituted heterocycles for treating cancers with egfr mutations
TW202529768A (zh) 癌症治療的療法
JPWO2021214117A5 (https=)
WO2025038698A1 (en) Crystalline forms of a pi3k inhibitor and uses of same
RU2007131101A (ru) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
JP2018509442A (ja) Fgfr4阻害剤としてのホルミル化n−複素環式誘導体
JP2021501140A5 (https=)
AU2019408244B2 (en) Quinoline derivatives for use in the treatment or prevention of cancer
JP7152784B2 (ja) 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
RU2022129897A (ru) Галогенированные гетероарильные и другие гетероциклические ингибиторы киназы и их применение
US12162876B2 (en) Indazole kinase inhibitor and use thereof
US20220227716A1 (en) Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors
US20240368084A1 (en) Sting modulators, compositions, and methods of use
WO2025194014A1 (en) Hetero aryl modulators of apmap and uses thereof
WO2025100519A1 (ja) ジヒドロクロメン誘導体を含むがんの治療剤
CN117500803A (zh) 用于治疗具egfr突变的癌症的氨基取代杂环
RU2020136404A (ru) Определенные соединения пладиенолида и способы их применения